Will cancer cells metastasize while taking brigatinib/brigatinib?

Whether cancer cells will metastasize while taking Brigatinib (Brigatinib) is a matter of great concern to many patients with ALK-positive non-small cell lung cancer and their families. Brigatinib is a targeted drug with high affinity for ALK mutations. Its mechanism of action is to inhibit the proliferation and spread of cancer cells by inhibiting the activity of ALK tyrosine kinase and blocking the signaling pathways of cancer cells. Especially in terms of brain metastasis, brigatinib has strong penetration ability into the central nervous system and can control the spread of lesions in the brain to a certain extent.

Despite this,"Whether cancer cells will metastasize" cannot be generalized. Theoretically, taking brigatinib can significantly reduce the probability of cancer cell spread, but it cannot completely prevent all forms of metastasis, especially when some drug-resistant mutations gradually develop. If a patient develops resistance to brigatinib and fails to undergo genetic testing and treatment adjustments in a timely manner, it may lead to the progression of the original lesions or new metastases. For example, after a period of treatment, some patients will develop other drug resistance mechanisms other than EML4-ALK fusion mutations, such as activation of the EGFR and MET pathways, which in turn will cause cancer cells to migrate to bone, liver, brain and other parts of the body.

In addition, the anti-tumor effect of brigatinib requires patients to adhere to regular medication and be closely monitored. Once the drug is stopped due to side effects, missed doses, or the dose is reduced on one's own, the drug concentration may decrease, leaving an opportunity for cancer cells to fight back. Therefore, while taking brigatinib, it is recommended that patients undergo imaging review (such as CT or MRI) every 2-3 months to monitor whether there are new metastatic trends in the disease. At the same time, if clinical manifestations such as worsening cough, changes in neurological symptoms, abnormal liver function, etc. are found, one should also be alert to whether there are transfer signals.

Reference materials:https://www.alunbrig.com/